Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 ICD-10-CM code D75.81

Myelofibrosis. This condition encompasses both primary and secondary myelofibrosis.

For secondary myelofibrosis, code the underlying condition first.Use additional codes for any associated therapy-related myelodysplastic syndrome (D46.-) or adverse drug effects (T45.1X5).

Medical necessity for treatment of myelofibrosis is established based on the severity of the condition and its impact on the patient's health.Treatment is directed at managing symptoms, such as anemia and splenomegaly, and preventing complications.

Physicians diagnose myelofibrosis based on patient history, physical examination, and laboratory tests including complete blood count (CBC), genetic testing, and bone marrow biopsy. Imaging studies such as ultrasound, CT, and MRI may also be used. Treatment varies depending on the underlying cause and severity, ranging from blood transfusions and medications to splenectomy or stem cell transplant.

In simple words: Myelofibrosis is a serious blood disorder where the bone marrow, which makes blood cells, becomes scarred. This can lead to abnormal blood cell counts, anemia, weakness, an enlarged spleen, easy bruising, bone pain, and night sweats.

Myelofibrosis is a serious bone marrow disorder characterized by abnormal blood cell counts and bone marrow fibrosis.It can be primary (idiopathic) where the cause is unknown or secondary where it results from another condition like certain cancers or other blood disorders.

Example 1: A patient with a history of breast cancer presents with fatigue, an enlarged spleen, and abnormal blood counts. A bone marrow biopsy confirms a diagnosis of secondary myelofibrosis due to the underlying malignancy., A patient with no known underlying conditions experiences increasing fatigue, night sweats, and an enlarged spleen.After extensive testing, including a bone marrow biopsy, they are diagnosed with primary myelofibrosis., A patient receiving chemotherapy for lymphoma develops anemia and other blood abnormalities.A bone marrow biopsy reveals myelofibrosis as a side effect of the chemotherapy treatment.

Documentation should include complete patient history, physical exam findings, laboratory results (CBC, genetic tests, bone marrow biopsy), imaging reports (if applicable), and details of any underlying conditions contributing to the myelofibrosis.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.